<DOC>
	<DOCNO>NCT00351923</DOCNO>
	<brief_summary>This study compare immunogenicity safety MeMuRu-OKA vaccine administer subcutaneously use alternative administration route .</brief_summary>
	<brief_title>Immunogenicity/Safety Measles-Mumps-Rubella-Varicella Vaccine ( MeMuRu-OKA ) : Using Two Different Administration Routes</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Children must healthy birth weight &gt; 2000 g participate confirm suspected tuberculosis , immunosuppressive ( include HIV ) condition , neurological disorder , history allergic disease reaction , major congenital defect , chronical administration salicylate , fever ( axillary temperature ³ 37.5°C time vaccination ) exclude factor . Children pregnant mother negative history chickenpox also exclude study . Children must receive one dose ( ) MMR varicella least 6 week enter study . They must receive receive nonregistered drug vaccine within 30 day prior study start , immunosuppressant 14 day . Immunoglobulins blood product prohibit 6 month study , well vaccine foreseen protocol within 30 day vaccination . Children must measles , mumps , rubella varicella/zoster , expose disease within 30 day prior study start . Newborn infant ( &lt; 5 week age ) , pregnant woman without previous exposure chickenpox , immunodeficient person live household vaccinate child</criteria>
	<gender>All</gender>
	<minimum_age>11 Months</minimum_age>
	<maximum_age>22 Months</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>